Alain D. Baron, MD
President and CEO, Director
Alain Baron is a co-founder of Elcelyx Therapeutics and was named President and CEO upon the company’s formation in 2010. Dr. Baron is also a Venture Partner at Lightstone Ventures and held the role of Entrepreneur-in-Residence at its predecessor firm, Morgenthaler Ventures.
Prior to joining Morgenthaler, he was Senior Vice President of Research at Amylin Pharmaceuticals where he served in senior roles in R&D since 1999. Dr. Baron was instrumental in advancing clinical programs that have culminated in four successful endocrinology products (Byetta®, Bydureon®, Symlin® and Myalept®). Prior to joining industry, Dr. Baron had a successful academic career, most recently at Indiana University School of Medicine in Indianapolis, where he served as Professor of Medicine and Director, Division of Endocrinology and Metabolism. He has also held faculty positions in the Division of Endocrinology and Metabolism at University of California, San Diego, and the Veterans Administration Medical Center in San Diego. He is the recipient of several prestigious awards for his research in diabetes and vascular disease, including the 1996 Outstanding Clinical Investigator Award from the American Federation for Medical Research. He is also a past National Institutes of Health MERIT award recipient.
Dr. Baron is co-editor of the Ellenberg & Rifkin Textbook of Diabetes, has authored over 100 original publications and is an inventor on more than 40 patents. Dr Baron graduated from McGill University, Canada (B.S. in Biology with honors) and the Medical College of Georgia Augusta (MD). Postdoctoral studies were completed at the University of California, San Diego.